Last10K.com

Windtree Therapeutics Inc (WINT) SEC Filing 8-K Material Event for the period ending Tuesday, January 17, 2023

SEC Filings

WINT Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

WINT Annual Reports

WINT Quarterly Reports

WINT Corporate News

WINT Registration of Securities

Windtree Therapeutics Inc

HISTORY TOOLS
CIK: 850261 Ticker: WINT

View differences made from one to another to evaluate Windtree Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Windtree Therapeutics Inc.

Continue

Assess how Windtree Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Windtree Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Document And Entity Information
Ticker: WINT
CIK: 946486
Form Type: 8-K Corporate News
Accession Number: 0001437749-23-001281
Submitted to the SEC: Thu Jan 19 2023 9:03:05 AM EST
Accepted by the SEC: Thu Jan 19 2023
Period: Tuesday, January 17, 2023
Industry: Biological Products No Disgnostic Substances
Events:
  1. Event for Officers

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/wint/0001437749-23-001281.htm